Takeshi Hatanaka

84PUBLICATIONS
127CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyRadiation therapySocial program evaluation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (84)

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|May 22, 2026
Compensatory Hepatic Hypertrophy After Carbon Ion Radiotherapy for Hepatocellular Carcinoma: Factors Associated With Its Development and Relationship With Prognosis.

|May 11, 2026
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

|Apr 29, 2026
Efficacy and Safety of Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma in the Caudate Lobe: A Comparative Study With Radiofrequency Ablation.

Pageof 14

Frequent Collaborators

62 joint publications

Atsushi Naganuma

56 joint publications

Satoru Kakizaki

51 joint publications

Toshifumi Tada

50 joint publications

Hidenori Toyoda